Liver Diseases  >>  bardoxolone methyl (RTA 402)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bardoxolone methyl (RTA 402) / Kyowa Kirin, Biogen
NCT00550849: Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction

Terminated
1/2
16
US
RTA 402
Reata, a wholly owned subsidiary of Biogen
Liver Disease
11/07
11/07

Download Options